CARL ZEISS MEDITEC AG - BR (AFX.DE) Fundamental Analysis & Valuation

FRA:AFX • DE0005313704

25.04 EUR
-0.34 (-1.34%)
Last: Mar 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This AFX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

AFX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 65 industry peers in the Health Care Equipment & Supplies industry. AFX has only an average score on both its financial health and profitability. AFX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

4

1. AFX.DE Profitability Analysis

1.1 Basic Checks

  • AFX had positive earnings in the past year.
  • AFX had a positive operating cash flow in the past year.
  • In the past 5 years AFX has always been profitable.
  • AFX had a positive operating cash flow in each of the past 5 years.
AFX.DE Yearly Net Income VS EBIT VS OCF VS FCFAFX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

1.2 Ratios

  • The Return On Assets of AFX (4.15%) is better than 61.54% of its industry peers.
  • The Return On Equity of AFX (6.67%) is comparable to the rest of the industry.
  • AFX has a Return On Invested Capital (5.79%) which is comparable to the rest of the industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for AFX is below the industry average of 10.72%.
Industry RankSector Rank
ROA 4.15%
ROE 6.67%
ROIC 5.79%
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
AFX.DE Yearly ROA, ROE, ROICAFX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10

1.3 Margins

  • AFX has a Profit Margin (6.34%) which is in line with its industry peers.
  • In the last couple of years the Profit Margin of AFX has declined.
  • With a Operating Margin value of 10.03%, AFX perfoms like the industry average, outperforming 46.15% of the companies in the same industry.
  • In the last couple of years the Operating Margin of AFX has declined.
  • The Gross Margin of AFX (52.76%) is worse than 60.00% of its industry peers.
  • In the last couple of years the Gross Margin of AFX has remained more or less at the same level.
Industry RankSector Rank
OM 10.03%
PM (TTM) 6.34%
GM 52.76%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
AFX.DE Yearly Profit, Operating, Gross MarginsAFX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. AFX.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AFX is creating some value.
  • Compared to 1 year ago, AFX has about the same amount of shares outstanding.
  • AFX has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, AFX has an improved debt to assets ratio.
AFX.DE Yearly Shares OutstandingAFX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
AFX.DE Yearly Total Debt VS Total AssetsAFX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • AFX has an Altman-Z score of 2.82. This is not the best score and indicates that AFX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • AFX's Altman-Z score of 2.82 is in line compared to the rest of the industry. AFX outperforms 53.85% of its industry peers.
  • The Debt to FCF ratio of AFX is 4.41, which is a neutral value as it means it would take AFX, 4.41 years of fcf income to pay off all of its debts.
  • With a Debt to FCF ratio value of 4.41, AFX perfoms like the industry average, outperforming 56.92% of the companies in the same industry.
  • A Debt/Equity ratio of 0.27 indicates that AFX is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.27, AFX is in the better half of the industry, outperforming 63.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 4.41
Altman-Z 2.82
ROIC/WACC0.86
WACC6.72%
AFX.DE Yearly LT Debt VS Equity VS FCFAFX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 2.35 indicates that AFX has no problem at all paying its short term obligations.
  • AFX has a better Current ratio (2.35) than 70.77% of its industry peers.
  • AFX has a Quick Ratio of 1.44. This is a normal value and indicates that AFX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.44, AFX is in the better half of the industry, outperforming 70.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 1.44
AFX.DE Yearly Current Assets VS Current LiabilitesAFX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AFX.DE Growth Analysis

3.1 Past

  • AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.51%.
  • AFX shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.28% yearly.
  • Looking at the last year, AFX shows a small growth in Revenue. The Revenue has grown by 5.89% in the last year.
  • AFX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.78% yearly.
EPS 1Y (TTM)-17.51%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-83.33%
Revenue 1Y (TTM)5.89%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.94% on average over the next years. This is quite good.
  • AFX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.17% yearly.
EPS Next Y1.24%
EPS Next 2Y12.96%
EPS Next 3Y14.01%
EPS Next 5Y14.94%
Revenue Next Year2.21%
Revenue Next 2Y3.76%
Revenue Next 3Y4.34%
Revenue Next 5Y5.17%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AFX.DE Yearly Revenue VS EstimatesAFX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
AFX.DE Yearly EPS VS EstimatesAFX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. AFX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 17.15, which indicates a rather expensive current valuation of AFX.
  • 86.15% of the companies in the same industry are more expensive than AFX, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 26.29, AFX is valued a bit cheaper.
  • The Price/Forward Earnings ratio is 12.19, which indicates a correct valuation of AFX.
  • 87.69% of the companies in the same industry are more expensive than AFX, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of AFX to the average of the S&P500 Index (24.60), we can say AFX is valued rather cheaply.
Industry RankSector Rank
PE 17.15
Fwd PE 12.19
AFX.DE Price Earnings VS Forward Price EarningsAFX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AFX is valued cheaper than 87.69% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, AFX is valued cheaply inside the industry as 84.62% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 16.81
EV/EBITDA 7.87
AFX.DE Per share dataAFX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • AFX's earnings are expected to grow with 14.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)13.79
PEG (5Y)5.23
EPS Next 2Y12.96%
EPS Next 3Y14.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. AFX.DE Dividend Analysis

5.1 Amount

  • AFX has a Yearly Dividend Yield of 2.17%. Purely for dividend investing, there may be better candidates out there.
  • In the last 3 months the price of AFX has falen by -42.36%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • Compared to an average industry Dividend Yield of 1.01, AFX pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.82, AFX has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.17%

5.2 History

  • The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
AFX.DE Yearly Dividends per shareAFX.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • 37.19% of the earnings are spent on dividend by AFX. This is a low number and sustainable payout ratio.
DP37.19%
EPS Next 2Y12.96%
EPS Next 3Y14.01%
AFX.DE Yearly Income VS Free CF VS DividendAFX.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M
AFX.DE Dividend Payout.AFX.DE Dividend Payout, showing the Payout Ratio.AFX.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

AFX.DE Fundamentals: All Metrics, Ratios and Statistics

CARL ZEISS MEDITEC AG - BR

FRA:AFX (3/6/2026, 7:00:00 PM)

25.04

-0.34 (-1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)05-11
Inst Owners24.4%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.24B
Revenue(TTM)2.20B
Net Income(TTM)141.22M
Analysts66.09
Price Target37.68 (50.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.17%
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.12%
PT rev (3m)-32.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-15.87%
EPS NY rev (3m)-20.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.94%
Revenue NY rev (3m)-2.58%
Valuation
Industry RankSector Rank
PE 17.15
Fwd PE 12.19
P/S 1.01
P/FCF 16.81
P/OCF 10.67
P/B 1.06
P/tB 4.63
EV/EBITDA 7.87
EPS(TTM)1.46
EY5.83%
EPS(NY)2.05
Fwd EY8.2%
FCF(TTM)1.49
FCFY5.95%
OCF(TTM)2.35
OCFY9.37%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)13.79
PEG (5Y)5.23
Graham Number27.88
Profitability
Industry RankSector Rank
ROA 4.15%
ROE 6.67%
ROCE 7.81%
ROIC 5.79%
ROICexc 5.89%
ROICexgc 14.08%
OM 10.03%
PM (TTM) 6.34%
GM 52.76%
FCFM 5.98%
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 4.41
Debt/EBITDA 1.61
Cap/Depr 60.61%
Cap/Sales 3.44%
Interest Coverage 10.38
Cash Conversion 60%
Profit Quality 94.37%
Current Ratio 2.35
Quick Ratio 1.44
Altman-Z 2.82
F-Score6
WACC6.72%
ROIC/WACC0.86
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.51%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-83.33%
EPS Next Y1.24%
EPS Next 2Y12.96%
EPS Next 3Y14.01%
EPS Next 5Y14.94%
Revenue 1Y (TTM)5.89%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%
Revenue Next Year2.21%
Revenue Next 2Y3.76%
Revenue Next 3Y4.34%
Revenue Next 5Y5.17%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year51.32%
EBIT Next 3Y23.17%
EBIT Next 5Y16.25%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%

CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ

What is the fundamental rating for AFX stock?

ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.


What is the valuation status of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?

ChartMill assigns a valuation rating of 6 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?

CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.


What are the PE and PB ratios of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?

The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 17.15 and the Price/Book (PB) ratio is 1.06.


Is the dividend of CARL ZEISS MEDITEC AG - BR sustainable?

The dividend rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 4 / 10 and the dividend payout ratio is 37.19%.